medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 4

<< Back Next >>

Ann Hepatol 2012; 11 (4)

Hepatitis C viral kinetics in Latino patients: a comparison to African American and Caucasian patients

Rodríguez-Torres M, Burguera J, Hallman D, Rodríguez-Orengo J, Echeandia M

Language: English
References: 22
Page: 450-463
PDF size: 592.01 Kb.


ABSTRACT

Introduction. Response to hepatitis C treatment is known to differ by race; and, limited data suggests by ethnicity as well. A lower efficacy of HCV therapy in Latinos has been observed; whether higher doses may improve the response is unknown. Material and methods. This study used the available data from the patients enrolled in the PROGRESS study and stratified it by race and ethnicity. The primary objectives were to evaluate the early viral kinetic pattern in Latino patients and to assess whether it was improved by higher doses of Peg-IFN alfa-2a and/or RBV, as compared to Caucasian and African American patients. Results. From a total of 1145 patients, 51 (4%) were classified Latino, 886 (77%) Caucasian, 124 (11%) African American and 84 (7%) other. Latinos had a similar virological response between the treatment groups at week 4; but by week 12, achieved a greater response with the higher intensified dose of peginterferon alfa-2a, and remained so at week 72. Caucasians had a greater response at week 4 and week 12 with the intensified dose; but by week 72, the response became similar between the treatment groups. The virological responses for African Americans were unaffected by the doses; and by week 12, were lower than both Latinos and Caucasians. In conclusion, this retrospective analysis provides further evidence for racial/ethnic differences in the response to peginterferon alfa-2a (40KD) plus ribavirin therapy in patients with HCV. Although the sample sizes in this analysis are small for generalized conclusions, the findings are of importance to physicians treating Latinos.


REFERENCES

  1. Missiha S, Heathcote J, Arenovich T, Khan K. Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007; 102(10): 2181-8.

  2. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, Joh T. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30(3): 787-93.

  3. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley- Lucas TE, Afdhal N, Brown RS, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131(2): 470-7.

  4. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350(22): 2265-71.

  5. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey V, Hamzeh FM, Martin P. Peginterferon alfa- 2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med 2009; 360(3): 257-67.

  6. An Older and More Diverse Nation by Midcentury: US Census Bureau. US Census Bureau. 14-8-0008. 12-5-2011.

  7. Pérez CM, Albizu C, Peña M, Torres EA, Reyes JC, Colón H, Ortiz AP, et al. Hepatitis C in Puerto Rico: a time for public health action. PR Health Sci J 2007; 26(4): 395-400.

  8. Pérez CM, Marrero E, Meléndez M, Adrovet S, Colón H, Ortiz AP, Soto-Salgado M, et al. Seroepidemiology of viral hepatitis, HIV and herpes simplex type 2 in the household population aged 21-64 years in Puerto Rico. BMC Infect Dis 2010; 23(10): 76.

  9. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis Crelated mortality in the United States, 1995-2004. Hepatology 2008; 47(4): 1128-35.

  10. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144(10): 705-14.

  11. Rodriguez-Torres M. Latinos and chronic hepatitis C: a singular population. Clin Gastroenterol Hepatol 2008; 6(5): 484-90.

  12. Lepe R, Layden-Almer JE, Layden TJ, Cotler S. Ethnic differences in the presentation of chronic hepatitis C. J Viral Hepat 2006; 13(2): 116-20.

  13. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, et al. Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance. Nature 2009; 461: 399-401.

  14. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, Hong L, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52(6): 1888-96.

  15. Chevaliez S, Hézode C. IL28B polymorphisms and chronic hepatitis C. Gastroenterol Clin Biol 2010; 34(11): 587-9.

  16. Ridruejo E, Solano A, Marciano S, Galdame O, Adrover R, Cocozzella D, Delettieres D, et al. Genetic variation in Interleukin- 28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. Ann Hepatol 2011; 10(4): 452-7.

  17. Moucari R, Ripault MP, Oulès V, Martinot-Peignoux M, Asselah T, Boyer N, El Ray A, et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy. J Hepatol 2007; 46(4): 596-604.

  18. Yu ML, Chuang WL, Dai CY, Lee LP, Hsieh MY, Lin ZY, Chen SC, et al. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy. Transl Res 2006; 148(3): 120-7.

  19. Reddy KR, Shiffman ML, Rodriguez-Torres M, Cheinquer H, Abdurakhmanov D, Bakulin I, Morozov V, et al. Intensified peginterferon alfa-2a/ribavirin therapy for patients with HCV genotype 1, weight ≥ 85 kg and high viral load: randomized trial. Gastroenterology 2010; 139(6): 1972-83.

  20. Martinot-Peignoux M, Maylin S, Moucari R, Ripault MP, Boyer N, Cardoso AC, Giuily N, et al. Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. Antivir Ther 2009; 14(4): 501-11.

  21. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011; 55(1): 69-75.

  22. Murphy AA, Herrmann E, Osinusi AO, Wu L, Sachau W, Lempicki RA, Yang J, et al. Twice-weekly pegylated interferon- α-2a and ribavirin results in superior viral kinetics in HIV/ hepatitis C virus co-infected patients compared to standard therapy. AIDS 2011; 25(9): 1179-87.




2020     |     www.medigraphic.com